Several pharmaceutical companies have developed H3R antagonists/inverse agonists, which weakly (<2-fold) and transiently increase brain histamine levels30, for the treatment of obesity, Alzheimer’s disease and schizophrenia32. The gene discussed is HRH3; the disease is early-onset autosomal dominant Alzheimer disease.